Harwood Feffer LLP Announces Investigation of Pharmacyclics, Inc.

NEW YORK, March 5, 2015 /PRNewswire/ -- Harwood Feffer LLP (www.hfesq.com) is investigating potential claims against the board of directors of Pharmacyclics, Inc. ("Pharmacyclics" or the "Company") (NASDAQ: PCYC) concerning the proposed acquisition of the Company by AbbVie Inc. ("AbbVie").      

Under the terms of the transaction, the Abbvie would purchase Pharmacyclics in a transaction valued at approximately $21 billion.  Pharmacyclics shareholders would receive approximately $261.25 per share, consisting of cash and AbbVie common stock.  Pharmacyclics shareholders will have the election of cash, stock, or a combination. 

Our investigation concerns whether the AbbVie board of directors is fulfilling its fiduciary duties, maximizing the value of the Company, disclosing all material benefits and costs, and obtaining full and fair consideration for Company stockholders. 

If you own AbbVie shares and wish to discuss this matter with us, or have any questions concerning your rights and interests with regard to this matter, please contact:

Benjamin I. Sachs-Michaels, Esq.
Robert I. Harwood, Esq.
Harwood Feffer LLP
488 Madison Avenue
New York, New York 10022
Phone Numbers: (877) 935-7400
(212)935-7400
Email: bsachsmichaels@hfesq.com
Website: http://www.hfesq.com 
Follow us on Twitter: @HarwoodFeffer

Harwood Feffer has been representing individual and institutional investors for many years, serving as lead counsel in numerous cases in federal and state courts. Please visit the Harwood Feffer LLP website (http://www.hfesq.com) for more information about the firm.

Attorney Advertising. The law firm responsible for this advertisement is Harwood Feffer LLP (www.hfesq.com). Prior results do not guarantee or predict a similar outcome with respect to any future matter.

Logo - http://photos.prnewswire.com/prnh/20120215/MM54604LOGO

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/harwood-feffer-llp-announces-investigation-of-pharmacyclics-inc-300046392.html

SOURCE Harwood Feffer LLP